Caenorhabditis elegans is a useful model for anthelmintic discovery

Area of Science:

• Drug Discovery
• Parasitology
• Genetics

Background:

• Parasitic nematodes infect a quarter of the global population, impacting human health, agriculture, and livestock.
• Existing anthelmintic drugs face increasing resistance, necessitating the development of novel treatments.
• Current drug screening methods are often costly and labor-intensive, with limited success in identifying new anthelmintics.

Purpose of the Study:

• To identify novel anthelmintic compounds through a large-scale chemical screen.
• To validate the efficacy of identified compounds against parasitic nematodes and in vertebrate models.
• To assess the potential for resistance development to new anthelmintics using genetic screens.

Main Methods:

• Screening of 67,012 compounds against the nematode Caenorhabditis elegans.
• Rescreening of hit compounds against two parasitic nematode species and two vertebrate models (HEK293 cells, zebrafish).
• Large-scale genetic screens of 19 million C. elegans mutants to predict resistance development.

Main Results:

• Identification of 30 structurally distinct anthelmintic lead molecules.
• Demonstration of lead compound efficacy in parasitic nematodes and vertebrate models.
• Identification of nematicides with low and high likelihoods of resistance generation.
• Discovery of a lead compound targeting complex II of the electron transport chain with high specificity and potency.

Conclusions:

• Caenorhabditis elegans serves as an effective and cost-efficient model system for anthelmintic drug discovery.
• The identified lead molecules represent promising candidates for the development of new treatments against parasitic nematode infections.
• Understanding resistance mechanisms is crucial for the sustainable use of novel anthelmintics.